Skip to main content
SpringerLink
Log in

Efalizumab Therapy for Psoriasis in Patients with Inadequate Responses to Etanercept

  • Case Report
  • Published:
American Journal of Clinical Dermatology Aims and scope Submit manuscript

Abstract

Efalizumab is a recombinant humanized monoclonal antibody approved for the treatment of adult patients with moderate-to-severe chronic plaque psoriasis. We present six cases of favorable response to efalizumab therapy in patients with psoriasis who demonstrated inadequate response or who were nonresponders to treatment with etanercept, a tumor necrosis factor-α-binding fusion protein. The subsequent response of these patients suggests that efalizumab may be a viable treatment option for patients with psoriasis who respond poorly to etanercept.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Jullien D, Prinz JC, Langley RGB, et al. T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva™): mechanisms of action. Dermatology 2004; 208: 297–306

    Google Scholar 

  2. Krueger GG. Current concepts and review of alefacept in the treatment of psoriasis. Dermatol Clin 2004; 22 (4): 407–26, viii

    Article  PubMed  CAS  Google Scholar 

  3. Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005; 152 (6): 1304–12

    Article  PubMed  CAS  Google Scholar 

  4. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, doubleblind trial. Lancet 2005; 366 (9494): 1367–74

    Article  PubMed  CAS  Google Scholar 

  5. Gottlieb AB, Feldman S, Weinstein G, et al. Infliximab: one year results [poster no. P43]. 64th Annual Meeting of the American Academy of Dermatology; 2006 Mar 3-7; San Francisco (CA)

    Google Scholar 

  6. Langley R, Leonardi C, Toth D, et al. Long-term safety and efficacy of adalimumab in the treatment of moderate to severe chronic plaque psoriasis [abstract]. 14th European Academy of Dermatology and Venereology Congress; 2005 Oct 12-15; London

    Google Scholar 

  7. Tyring S, Poulin Y, Langley R, et al. A 96-week phase III study of safety and efficacy of etanercept 50mg twice weekly in patients with psoriasis [abstract]. J Am Acad Dermatol 2006; 54 Suppl. 3: AB10

    Google Scholar 

  8. Gordon KB, Papp KA, Hamilton TK, et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003; 290 (23): 3073–80

    Article  PubMed  CAS  Google Scholar 

  9. Menter A, Hamilton TK, Caro I, et al. Safety and tolerability of efalizumab therapy for patients with moderate to severe chronic plaque psoriasis: results of an open-label phase IIIb multicenter trial [abstract]. 63rd Annual Meeting of the American Academy of Dermatology; 2005 Feb 18-22; New Orleans (LA)

    Google Scholar 

  10. Gottlieb AB, Gordon KB, Hamilton TK, et al. Maintenance of efficacy and safety with continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: final phase IIIb study results [abstract]. 63rd Annual Meeting of the American Academy of Dermatology; 2005 Feb 18-22; New Orleans (LA)

    Google Scholar 

  11. Krueger GG, Feldman SR, Camisa C, et al. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 2000; 43 (2 Pt 1): 281–5

    Article  PubMed  CAS  Google Scholar 

  12. Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol 2005; 152 (5): 861–7

    Article  PubMed  CAS  Google Scholar 

  13. Enbrel® (etanercept) [package insert]. Thousand Oaks (CA): Immunex Corporation, 2006 Apr

  14. Raptiva® (efalizumab) [package insert]. South San Francisco (CA): Genentech, Inc., 2005 Jun

Download references

Acknowledgments

The authors received no direct compensation for preparation of this manuscript. Patricia Segarini, PhD, Sabrina Cheng, MD, and Blesila Castro, PhD, of Helix Medical Communications LLC provided medical writing support on behalf of Genentech, Inc. Dr Kramer acts as a consultant to and has received speaker’s honoraria from Amgen, Genentech, and Abbott. Dr Turner is as an advisor, principal investigator, and member of the speakers’ bureau for Genentech.

Author information

Authors and Affiliations

  1. Dermatology Division, Mercy Medical Group, 3000 Q Street, Sacramento, California, 95816, USA

    Jesse M. Kramer

  2. Mid-South Dermatology and Skin Cancer Center, Memphis, Tennessee, USA

    James E. Turner

Authors
  1. Jesse M. Kramer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James E. Turner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jesse M. Kramer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kramer, J.M., Turner, J.E. Efalizumab Therapy for Psoriasis in Patients with Inadequate Responses to Etanercept. Am J Clin Dermatol 10, 134–140 (2009). https://doi.org/10.2165/00128071-200910020-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128071-200910020-00008

Keywords

Search

Navigation